



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board


Performance & Finance Committee Cancer Update

November 2022




Performance

Single Cancer Pathway Performance – To Oct 22




	Aug 2021	Sep 2021	Oct 2021	Nov 2021	Dec 2021	Jan 2022	Feb 2022	Mar 2022	Apr 2022	May 2022	Jun 2022	Jul 2022	Aug 2022	Sep 2022	Oct 2022
% - 1st Submission	58%	62%	62%	63%	54%	54%	54%	54%	48%	47%	51%	56%	55%	57%	42%
Actual %	60%	63%	64%	63%	56%	56%	56%	58%	51%	48%	53%	56%	57%		
Target - 75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%
Trajectory	55%	62%	66%	63%	66%	68%	58%	70%	70%	67%	66%	69%	67%	74%	77%

August 2022 - Proportions treated




Proportion of patients treated beyond target by Tumour Site
April 2021 - August 2022



Backlog Trajectories

All Sites - Backlog Trajectory v Actual reported totals




- Total volume 2% higher than this time last = 54 patients
- Backlog is now 545.
- The **top 4 tumour sites** with backlog are:
 1. Lower GI – 169/31% - a **decrease** of 19 patients, (↓3%).
 - a. 70% at diagnostic stage (↓2%).
 - b. 38% waiting endoscopy (↑3%).
 - c. 10% waiting treatment (↓1%)
 2. Urology – 84/15% - **increase** of 5 patients
 - a. 51% (↑3%) at diagnostic stage
 - b. 31% waiting follow-up (↓2%).
 - c. 15% waiting treatment (↑1%)
 3. Upper GI – 78/14% - an **increase** of 2 patients
 - a. 58% at diagnostic stage (↓4%).
 - b. 35% waiting endoscopy (↓2%).
 - c. 12% waiting treatment
 4. Gynaecology – 71/13% - **increase** of 6 patients, ↑1%
 - a. 58% at diagnostic stage of pathway (↑5%).
 - b. 20% waiting 'One Stop'/PMB clinic.
 - c. 18% waiting treatment (↓3%).



Overview – demand (new suspicions of cancer)

New Suspicion of Cancer	Dec-20	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22
Acute Leukaemia	4	0	2	2	2	1	0	2	0	1	2	1	0	0	1	3	1	1	1	0	0
Brain CNS	4	2	5	7	6	7	6	4	5	4	0	2	5	4	5	5	0	7	5	11	14
Children's Cancer	0	4	0	0	1	1	0	0	0	1	3	1	1	2	2	1	7	10	8	4	8
Breast	172	184	198	239	226	239	211	177	146	242	224	223	158	192	181	171	143	198	179	158	166
Gynaecological	140	180	183	215	203	224	234	239	201	225	197	197	168	185	198	218	192	0	202	209	269
Haematological	21	9	23	20	23	18	25	24	15	15	25	13	15	13	5	18	10	25	26	13	15
Head & Neck	103	122	149	171	195	183	192	193	152	162	145	166	119	135	167	176	170	0	154	201	218
Lower GI	222	272	268	342	362	343	350	385	330	424	373	354	361	361	330	381	342	501	453	543	502
Lung	36	27	38	50	60	48	51	49	43	55	47	38	32	49	51	39	49	0	52	88	86
Other	74	58	67	73	67	75	102	90	49	58	53	58	42	70	54	65	57	70	61	83	85
Sarcoma	55	65	57	59	81	59	71	67	63	68	42	45	35	48	44	53	16	18	22	23	34
Skin	224	262	269	336	320	322	359	407	303	363	285	303	234	252	268	360	348	390	351	339	428
Upper GI	142	159	175	229	189	195	256	255	256	241	289	228	214	260	237	242	189	292	246	272	313
Urological	143	131	160	189	145	156	157	170	179	146	136	142	133	137	120	156	118	130	138	148	203
Monthly Totals	1340	1475	1594	1932	1880	1871	2014	2062	1742	2005	1821	1771	1517	1708	1663	1888	1642	1642	1898	2092	2341
Quarterly Totals							5818			8.8% increase between same quarter 21/22									6331		



PTL Comparison Nov-21 to Nov 22

Cancer PTL - 19th November 2021

Tumour Site	Days W/	0 - 10	11-20	21 - 31	32 - 42	43 - 52	53 - 62	63 - 100	> 100	Grand Total
Lower Gastrointestinal		51	107	130	93	83	58	165	142	829
Breast		100	65	86	86	66	12	34	15	464
Gynaecological		71	46	74	48	46	23	38	18	364
Upper Gastrointestinal		52	89	64	31	28	14	33	29	340
Skin		114	70	69	22	19	7	27	10	338
Urological		45	42	33	25	20	11	67	75	318
Other		118	14	14	6	7	2	3	1	165
Head and Neck		43	20	19	12	10	8	17	13	142
Lung		4	6	10	13	8	9	23	21	94
Sarcoma		7	7	12	4	2	2	5	1	40
Haematological		5	6	2	4	4		9	10	40
Brain/CNS							1		2	3
Children's Cancer			1	1						2
Unknown Primary						1				1
Grand Total		610	473	514	344	294	147	421	337	3140

Cancer PTL - 10th November 2022

Tumour Site	Days W/	0 - 10	11 - 20	21 - 31	32 - 42	43 - 52	53 - 62	63 - 100	>100	Grand Total
Lower Gastrointestinal		89	100	149	86	91	72	132	83	802
Gynaecological		66	60	102	69	58	29	59	31	474
Skin		75	93	126	48	22	19	57	24	464
Upper Gastrointestinal		50	69	86	50	35	25	51	43	409
Urological		48	26	33	19	18	11	53	45	253
Head and Neck		63	37	48	19	26	5	21	10	229
Breast		42	20	21	12	12	3	18	7	135
Other		66	29	14		5	4	8	3	129
Lung		16	10	14	12	8	12	22	19	113
Haematological		6	1	2	2	1	2	9	20	43
Sarcoma		2	5	8	2	6	5	4	7	39
Children's Cancer		3	2		2		1			8
Brain/CNS			1	1			1			3
Grand Total		526	453	604	321	282	189	434	292	3101

- Change in overall volume – 1.2% Reduction
- Biggest change by tumour site –

Tumour Site	+/-	% Change
Lower Gastrointestinal	-27.00	-3.3%
Breast	-329.00	-70.9%
Gynaecological	110.00	30.2%
Upper Gastrointestinal	69.00	20.3%
Skin	126.00	37.3%
Urological	-65.00	-20.4%
Other	-36.00	-21.8%
Head and Neck	87.00	61.3%
Lung	19.00	20.2%
Sarcoma	-1.00	-2.5%
Haematological	3.00	7.5%
Brain/CNS	0.00	0.0%
Children's Cancer	6.00	300.0%
Unknown Primary	-1.00	-100.0%
Grand Total	-39.00	-1.2%


- Volume > 62 days:
 - 2021 – 758
 - 2022 – 726
- > 100 days
 - 2021 – 337
 - 2022 – 292 (13%)



Key Tumour Sites – Urology, incl. NOP compliance

Source: DU SCP Compliance Dashboard – Urology, SBUHB

Indicator (see 'Metric Methodology')	Jul-22	Jun-22	May-22	Apr-22	Jul-21	Long Term Trend (24 Months)
Total Patients Treated	23 -4	27	47	30	29 -6	
Total Patients Treated, Downgraded or Deceased	119 -21	140	143	123	152 -33	
Percentage Straight to Test	70.2% 8.3%	61.9%	43.8%	50.6%	57.9% 12.3%	
First Appointment (Where Recorded) Within 10 Days	10 32% 15.8%	16.5%	31.2%	26.7%	17.3% 14.8%	
First Diagnostic Within 21 Days	21 51.3% 19.1%	32.1%	36.4%	40.7%	30.3% 21.0%	
Informed they <u>DO NOT</u> have Cancer, Within 28 Days	35.6% 5.5%	30.1%	14.3%	31.9%	23.8% 11.8%	
Informed they <u>DO</u> have Cancer, Within 28 Days	6.8% -1.8%	8.6%	5.1%	5.8%	5.0% 1.8%	
Treatment Within 21 Days of DTT	73.9% -3.9%	77.8%	66.0%	66.7%	62.1% 11.8%	
First Definitive Treatment Within 62 Days	60.9% 16.4%	44.4%	34.0%	36.7%	34.5% 26.4%	



- Urology is the main contributor to poor overall performance, with the largest volume of breaches. This reflects the plan for backlog removal.
- Is the 2nd largest proportion of patients in backlog that has been increasing over recent weeks.
- Diagnostic waits are a main factor for poor performance, TURBT accounting for a significant proportion (TURBT no longer a 'stop clock' for all patients).
- TURBT – low risk patients now have this procedure at NPTH. High risk patients needing access at Morriston that impacts pathway due to unscheduled care pressures.
- Capacity for RALP at UHW is an issue – needs further engagement with C&VUHB colleagues. Meeting arranged for end of November
- Complex, non-Swansea Bay referrals

Improvement Plan


- Development of Enhanced Recovery Unit at NPTH will reduce demand for "Morriston only" lists.
- Weekly focussed meetings with Service, including consultant urologist and pathology input.
- Increased capacity for 1st outpatient and follow-up appointments to reduce time to DDT.



Key Tumour Sites – Breast, incl. NOP compliance

Source: DU SCP Compliance Dashboard – Breast, SBUHB

Indicator (see 'Metric Methodology')	Jul-22	Jun-22	May-22	Apr-22	Jul-21	Long Term Trend (24 Months)
Total Patients Treated	24 -6	30	24	20	40 -16	
Total Patients Treated, Downgraded or Deceased	187 -33	220	152	145	222 -35	
Percentage Straight to Test	96.1% -2.5%	98.5%	98.6%	97.0%	96.5% -0.4%	
First Appointment (Where Recorded) Within 10 Days	10 9% 5.3%	3.2%	5.9%	2.1%	2.7% 5.3%	
First Diagnostic Within 21 Days	21 12.8% 4.7%	8.2%	12.5%	8.3%	11.3% 1.6%	
Informed they DO NOT have Cancer, Within 28 Days	3.8% 3.8%	0.0%	3.4%	8.0%	11.2% -7.3%	
Informed they DO have Cancer, Within 28 Days	38.5% 16.6%	21.9%	6.9%	8.0%	8.9% 29.5%	
Treatment Within 21 Days of DTT	50.0% 26.7%	23.3%	29.2%	5.0%	62.5% -12.5%	
First Definitive Treatment Within 62 Days	37.5% 17.5%	20.0%	20.8%	10.0%	67.5% -30.0%	



- Significant progress made within backlog this year. Is ahead of profile, now 10 patients above end of March 2023 trajectory.
- Breaches are primarily due to waits to the triple assessment clinic or for surgery at Morriston - waits are reducing.
- One-stop clinics maintained 100%.
- Time to Treatment waits are reducing.
- Recent recruitment to Consultant Surgeon (x2) and Radiologist (x1.5) vacancies.

Improvement Plan



- Addition Mammogram machine to be in commission by end of Q3.
- WLI's are being undertaken to reduce backlog and improve waits until the additional mammogram is in service (approx 60 sessions since Feb-22 via 6-day working).
- Imminent commissioning of Enhanced Recovery Unit at Singleton Hospital will reduce demand for Morriston theatres/bed capacity for complex surgery/high risk patients.



Key Tumour Sites – Lower GI, incl. NOP compliance

Source: DU SCP Compliance Dashboard – LGI, SBUHB

Indicator (see 'Metric Methodology')	Jul-22	Jun-22	May-22	Apr-22	Jul-21	Long Term Trend (24 Months)
Total Patients Treated	25 -2	27	24	28	41 -16	
Total Patients Treated, Downgraded or Deceased	419 63	356	342	264	359 60	
Percentage Straight to Test	73.4% 8.3%	65.1%	64.3%	53.2%	57.0% 16.4%	
First Appointment (Where Recorded) Within 10 Days	10 12% -2.9%	14.8%	12.3%	22.1%	18.6% -6.7%	
First Diagnostic Within 21 Days	21 15.8% -3.3%	19.1%	20.8%	18.9%	31.8% -16.0%	
Informed they DO NOT have Cancer, Within 28 Days	11.6% -13.2%	24.8%	22.6%	26.8%	15.2% -3.6%	
Informed they DO have Cancer, Within 28 Days	4.2% 1.2%	3.0%	5.2%	3.9%	5.7% -1.5%	
Treatment Within 21 Days of DTT	24.0% -31.6%	55.6%	29.2%	46.4%	48.8% -24.8%	
First Definitive Treatment Within 62 Days	24.0% -13.0%	37.0%	33.3%	25.0%	26.8% -2.8%	



- Significant increase in referrals rates resulting in increased breach volumes.
- Has the highest proportion of patients in backlog.
- Operating capacity for complex patients is constrained at Morriston Hospital.
- High demand for Endoscopy causing diagnostic delays – plans in place to reduce waits to 2-3 weeks by end of December.
- Complex, non-SBUHB pelvic cases requiring increased capacity across multiple tumour sites.

Improvement Plan

- Working with WCN and DU to understand variation in demand / conversion rates.
- Working with Industry to map pathway (Amgen)
- Pathway redesign with Primary Care to reduce delays and support STT pathways. This will further reduce SCP waits for Endoscopy.
- Reducing variation between Surgical and Gastroenterology pathways to DDT
- Imminently commission Enhanced Recovery Unit at Singleton Hospital will reduce demand for Morriston theatres/bed capacity for complex surgery/high risk patients
- Swift response to change in referral guidance to appropriately manage demand.

